The case for inhibiting p38 mitogen-activated protein kinase in heart failure

This minireview discusses the evidence that the inhibition of p38 mitogen-activated protein kinases (p38 MAPKs) maybe of therapeutic value in heart failure. Most previous experimental studies, as well as past and ongoing clinical trials, have focussed on the role of p38 MAPKs in myocardial infarctio...

Descripción completa

Detalles Bibliográficos
Autores principales: Arabacilar, Pelin, Marber, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428223/
https://www.ncbi.nlm.nih.gov/pubmed/26029107
http://dx.doi.org/10.3389/fphar.2015.00102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428223/
https://www.ncbi.nlm.nih.gov/pubmed/26029107
http://dx.doi.org/10.3389/fphar.2015.00102

Ejemplares similares